Clinical Trials

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

25 enrolled

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

75 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

235 enrolled

Phase 2 Not yet recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

112 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT06511882 2026-02-27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

37 enrolled

Leukemia, Myeloid, Acute

NCT01515527 2026-02-06

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

160 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05799079 2026-01-09

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

1 enrolled 8 charts

Leukemia, Myeloid, Acute

NCT05184842 2026-01-05

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

91 enrolled 26 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04188405 2025-11-20

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT06429098 2025-09-04

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

40 enrolled

Leukemia, Myeloid, Acute

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02781883 2025-03-07

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

108 enrolled

Leukemia, Myeloid, Acute

NCT04476199 2025-01-06

Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

100 enrolled

Leukemia, Myeloid, Acute

NCT06379360 2024-12-27

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

77 enrolled

Leukemia, Myeloid, Acute

NCT06741722 2024-12-27

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

Leukemia, Myeloid, Acute

NCT06316960 2024-08-22

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

50 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06337331 2024-06-14

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04905810 2024-05-29

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Leukemia, Myeloid, Acute

NCT06046313 2024-03-05

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02441803 2024-02-22

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

11 enrolled 12 charts

Leukemia, Leukemia, Myeloid, Acute

NCT04055844 2023-11-07

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

14 enrolled 20 charts

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

5 enrolled 9 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03063203 2022-06-02

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

17 enrolled 20 charts

Recurrence, Leukemia, Myeloid, Acute

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04752527 2021-11-15

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

42 enrolled

Leukemia, Myeloid, Acute

NCT02190695 2021-05-19

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

92 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03080766 2021-04-28

The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype

Leukemia, Myeloid, Acute

NCT04541277 2020-09-09

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

55 enrolled

Leukemia, Myeloid, Acute

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

100 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04353479 2020-04-20

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

29 enrolled

Leukemia, Myeloid, Acute

NCT01786343 2020-04-15

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

74 enrolled 11 charts

Leukemia, Leukemia, Myeloid, Acute

NCT02252107 2020-03-19

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

46 enrolled

Leukemia, Myeloid, Acute

NCT01546038 2020-03-03

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

255 enrolled 82 charts 1 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01707004 2019-11-21

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

20 enrolled 19 charts

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01829503 2019-11-14

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

44 enrolled 20 charts

Leukemia, Myeloid, Acute

NCT00414310 2019-05-21

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

153 enrolled 8 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03146871 2019-04-18

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

7 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02532010 2018-06-15

Pacritinib

13 enrolled 10 charts

Leukemia, Myeloid, Acute

NCT03381781 2018-01-04

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

100 enrolled

Leukemia, Myeloid, Acute

NCT01607645 2017-03-31

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Classical hematologyOther hematologic neoplasm

7 enrolled 17 charts

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT02084563 2016-11-08

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Classical hematologyMyeloidOther hematologic neoplasm

455 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT00867672 2016-08-31

DECIDER

204 enrolled

Leukemia, Myeloid, Acute

NCT00778375 2016-07-14

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

122 enrolled 10 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02029417 2016-05-09

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2 enrolled 6 charts